Xiaoman Liu1, Siew-Kee Low1,2, Joshua R Atkins3,4,5, Jing Qin Wu3,5,6, William R Reay3,4,5, Heath M Cairns3,4,5, Melissa J Green7,8, Ulrich Schall4,5,9, Assen Jablensky10, Bryan Mowry11,12, Patricia T Michie4,13, Stan V Catts14,15, Frans Henskens4,9,16, Christos Pantelis17,18,19,20, Carmel Loughland4,9,13,21, Alan V Boddy1,22, Paul A Tooney3,4,5, Rodney J Scott3,4,23, Vaughan J Carr7,8,24, Murray J Cairns3,4,5. 1. School of Pharmacy, The University of Sydney, Sydney, NSW, Australia. 2. Project for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan. 3. School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia. 4. Hunter Medical Research Institute, Newcastle, New South Wales, Australia. 5. Centre for Brain & Mental Health Research, The University of Newcastle, Callaghan, NSW, Australia. 6. School of Life and Environmental Sciences, Faculty of Science, The University of Sydney. 7. School of Psychiatry, University of New South Wales, Sydney, NSW, Australia. 8. Neuroscience Research Australia, Sydney, NSW, Australia. 9. School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW, Australia. 10. Centre for Clinical Research in Neuropsychiatry, The University of Western Australia, Perth, WA, Australia. 11. Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia. 12. Queensland Centre for Mental Health Research, The University of Queensland, Brisbane, QLD, Australia. 13. School of Psychology, Faculty of Science, The University of Newcastle, Callaghan, NSW, Australia. 14. Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia. 15. School of Medicine, University of Queensland, Herston, QLD Australia. 16. Priority Research Centre for Health Behaviour and Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia. 17. Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health, Carlton, VIC, Australia. 18. The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia. 19. NorthWestern Mental Health, Sunshine Hospital, St Albans, VIC, Australia. 20. Centre for Neural Engineering, Department of Electrical and Electronic Engineering, The University of Melbourne, Carlton, VIC, Australia. 21. Hunter New England Health, Newcastle, NSW, Australia. 22. School of Pharmacy and Medical Sciences, UniSA Cancer Research Institute, University of South Australia, Adelaide, SA, Australia. 23. NSW Health Pathology, Newcastle, Australia. 24. Department of Psychiatry, School of Clinical Sciences, Monash University, Melbourne, VIC, Australia.
Abstract
OBJECTIVES: Large-scale genetic analysis of common variation in schizophrenia has been a powerful approach to understanding this complex but highly heritable psychotic disorder. To further investigate loci, genes and pathways associated more specifically in the well-characterized Australian Schizophrenia Research Bank cohort, we applied genome-wide single-nucleotide polymorphism analysis in these three annotation categories. METHODS: We performed a case-control genome-wide association study in 429 schizophrenia samples and 255 controls. Post-genome-wide association study analyses were then integrated with genomic annotations to explore the enrichment of variation at the gene and pathway level. We also examine candidate single-nucleotide polymorphisms with potential function within expression quantitative trait loci and investigate overall enrichment of variation within tissue-specific functional regulatory domains of the genome. RESULTS: The strongest finding (p = 2.01 × 10-6, odds ratio = 1.82, 95% confidence interval = [1.42, 2.33]) in genome-wide association study was with rs10252923 at 7q21.13, downstream of FZD1 (frizzled class receptor 1). While this did not stand alone after correction, the involvement of FZD1 was supported by gene-based analysis, which exceeded the threshold for genome-wide significance (p = 2.78 × 10-6). CONCLUSION: The identification of FZD1, as an independent association signal at the gene level, supports the hypothesis that the Wnt signalling pathway is altered in the pathogenesis of schizophrenia and may be an important target for therapeutic development.
OBJECTIVES: Large-scale genetic analysis of common variation in schizophrenia has been a powerful approach to understanding this complex but highly heritable psychotic disorder. To further investigate loci, genes and pathways associated more specifically in the well-characterized Australian Schizophrenia Research Bank cohort, we applied genome-wide single-nucleotide polymorphism analysis in these three annotation categories. METHODS: We performed a case-control genome-wide association study in 429 schizophrenia samples and 255 controls. Post-genome-wide association study analyses were then integrated with genomic annotations to explore the enrichment of variation at the gene and pathway level. We also examine candidate single-nucleotide polymorphisms with potential function within expression quantitative trait loci and investigate overall enrichment of variation within tissue-specific functional regulatory domains of the genome. RESULTS: The strongest finding (p = 2.01 × 10-6, odds ratio = 1.82, 95% confidence interval = [1.42, 2.33]) in genome-wide association study was with rs10252923 at 7q21.13, downstream of FZD1 (frizzled class receptor 1). While this did not stand alone after correction, the involvement of FZD1 was supported by gene-based analysis, which exceeded the threshold for genome-wide significance (p = 2.78 × 10-6). CONCLUSION: The identification of FZD1, as an independent association signal at the gene level, supports the hypothesis that the Wnt signalling pathway is altered in the pathogenesis of schizophrenia and may be an important target for therapeutic development.
Entities:
Keywords:
FZD1; Schizophrenia; Wnt signalling; gene-based analysis; genome-wide association study
Authors: Roudabeh Vakil Monfared; Wedad Alhassen; Tri Minh Truong; Michael Angelo Maglalang Gonzales; Vincent Vachirakorntong; Siwei Chen; Pierre Baldi; Olivier Civelli; Amal Alachkar Journal: Cells Date: 2021-10-31 Impact factor: 6.600
Authors: Haijun Han; Mengxiang Xu; Li Wen; Jiali Chen; Qiang Liu; Ju Wang; Ming D Li; Zhongli Yang Journal: Front Mol Neurosci Date: 2022-07-07 Impact factor: 6.261
Authors: Jolien Rijlaarsdam; Edward D Barker; Chiara Caserini; M Elisabeth Koopman-Verhoeff; Rosa H Mulder; Janine F Felix; Charlotte A M Cecil Journal: J Psychiatr Res Date: 2021-05-28 Impact factor: 4.791